Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chi-Med Reports CFDA Acceptance of Fruquintinib NDA Filing

publication date: Jun 12, 2017
Hutchison China MediTech (Chi-Med) announced the CFDA accepted the company's New Drug Application for its lead drug, the cancer treatment fruquintinib. In its China Phase III trial, fruquintinib increased survival by 41% in patients with advanced colorectal cancer. Chi-Med reported the data at the ASCO meeting in the US two weeks ago (see story).  The company said the acceptance triggers a milestone payment of $4.5 million from Lilly, its partner for the drug in China. More details....

Stock Symbols: (AIM/NSDQ: HCM) (NYSE: LLY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital